Medicenna Therapeutics Corp (NASDAQ:MDNA) dropped 10%, and in a month, the stock has shed 32%. The company announced the publication of its pre-clinical MDNA109 data in a peer-reviewed journal, Frontiers in Immunology, authored by University of Helsinki researchers and from other institutions. MDNA109 is the company’s IL-2 Superkine platform which forms MDNA11’s basis. CEO Fahar …